510
Participants
Start Date
June 30, 2004
Study Completion Date
August 31, 2005
sertraline/[S,S]-reboxetine
Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/4mg \[S,S\]-reboxetine for 5 and one half weeks.
sertraline/[S,S]-reboxetine
Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/6mg \[S,S\]-reboxetine for 5 and one half weeks.
sertraline
Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks.
sertraline
Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks
sertraline/[S,S]-reboxetine
Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/2mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg \[S,S\]-reboxetine for 5 and one half weeks.
Placebo
Tablets, orally once per day for 8 weeks
sertraline/[S,S]-reboxetine
Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine orally for 3 days, followed by 100mg sertraline/2mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg \[S,S\]-reboxetine for 5 and one half weeks
[S,S]-reboxetine monotherapy
Tablets, 2 mg/day orally for 3 days, followed by 4 mg/day orally for 4 and one half weeks, followed by 6mg/day for 3 weeks
Pfizer Investigational Site, Tallinn
Pfizer Investigational Site, Tartu
Pfizer Investigational Site, Viljandi
Pfizer Investigational Site, Pärnu
Pfizer Investigational Site, Moscow
Pfizer Investigational Site, Moscow
Pfizer Investigational Site, Moscow
Pfizer Investigational Site, Moscow
Pfizer Investigational Site, Saint Petersburg
Pfizer Investigational Site, Saint Petersburg
Pfizer Investigational Site, Saint Petersburg
Pfizer Investigational Site, Saint Petersburg
Pfizer Investigational Site, Smolensk
Pfizer Investigational Site, Rostov-on-Don
Pfizer Investigational Site, Kazan'
Pfizer Investigational Site, Tomsk
Pfizer Investigational Site, Moscow
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY